Three Kessler Foundation research scientists, Timothy Rich, PhD, OTR/L, and Co-Principal Investigators Helen Genova, PhD, and Heba Elsayed, MD, have been awarded $777,325 in federal grants by the National Institutes of Health (NIH) to expand research in the fields of neglect dyslexia and autism.0
Ocugen plans Phase I/II trials for macular disease gene therapies – Pharmaceutical Technology
Ocugen announced that the manufacturing facility for its regenerative cell therapy for cartilage, NeoCart, is expected for completion by the end of 2023. Image Credit: